SM-102

Nanopharmaceuticals Global Market Report 2022: Huge Market Potential in Pharmaceutical Companies for Development of Effective Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Pharmaceutical, Health, Infection, Value, CHF, Drug delivery, Neurology, Acquisition, Market share analysis, Growth, CAGR, Business Growth Fund, GBP, CAD, Use, JPY, Strategic management, Research, Incidence, AUD, Degenerative disease, SM-102, Application, Liposome, Decision-making, USD, Customer support, Retail, EUR, Oncology

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.

Key Points: 
  • The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF.
  • Based on Application, the market was studied across Anti-infective, Anti-inflammatory, Drug Delivery, Neurology, and Oncology.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Solid lipid nanoparticle, RNA, SaRNA, Development, Emergent, CMO, CMOS, BioNTech, MicroRNA, LNP, Plasmid, Merck, Diosynth, CGMP, Nucleic acid, Organization, Clinical trial, Research, Operation Warp Speed, Oncology, PTS, Merck Group, COVID-19, Commercial, AMRI, CDMO, Safety, CAGR, Technology, Viral Research and Diagnostic Laboratories, Vaccine, SM-102, Partnership, LPN, International, Nanoparticle, Prevalence, Contract, Drug development, FDB, Industry, Attention, Fine chemical, Pharmaceutical industry, Others

According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles (LNPs) CDMO services in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA, Emergent, Nucleic acid, Organization, Research, COVID-19, LNP, SM-102, LPN, Drug development, Solid lipid nanoparticle, Development, Plasmid, Merck, Partnership, PTS, Oncology, Merck Group, Commercial, Safety, Technology, Viral Research and Diagnostic Laboratories, International, Nanoparticle, Prevalence, SaRNA, CMO, CMOS, BioNTech, MicroRNA, Diosynth, Clinical trial, AMRI, CDMO, Attention, RNA transfection, CGMP, Operation Warp Speed, Vaccine, Contract, FDB, Industry, Fine chemical, Pharmaceutical industry, Others

This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.

Key Points: 
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Lipid nanoparticles provide the prospect of developing new therapies due to their unique size dependent features.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

Polypeptide Therapeutic Solutions (PTS) Announces Company Name Change to Curapath and Expansion of Drug Delivery Capabilities and Services

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Medical Supplies, LinkedIn, Time, RNA transfection, Therapy, Polymer, Vaccine, Technology transfer, GMP, Drug development, Tissue, SM-102, PAA, Arclin, Doctor of Philosophy, PTS, Excipient, Nanoparticle, DNA, LNP, Pharmaceutical industry

Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to Curapath .

Key Points: 
  • Polypeptide Therapeutic Solutions (PTS), a leader in the design, development, and custom manufacturing of polyamino-acid based delivery systems for vaccines and therapeutics, today announced the company has changed its name to Curapath .
  • As part of Curapaths transformation, the company has expanded existing capabilities in development and production of novel functional lipid and polymer excipients and nanoparticle formulations.
  • The expanded capabilities build upon the companys comprehensive portfolio of services which include development, formulation, analytical method development, GMP manufacturing, and fill and finish.
  • The company offers contract development and manufacturing services including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill/finish services.

2022 Tang Prize Masters' Forum Series Sheds Light on Current Global Challenges

Retrieved on: 
Friday, October 14, 2022
History, Tang Prize, Sustainable development, RNA transfection, Therapy, Government, YouTube, Constitution, SM-102, Technology, Student, Gold, Sinology, Exercise, DRS, Language, Optimism, Speech, RNA, LNP, California Cultures in Comparative Perspective, COVID-19, Weather, Medical device

TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September.

Key Points: 
  • TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September.
  • Six 2022 laureates, Professor Jeffrey Sachs for Sustainable Development, Drs.
  • Tens of thousands of students, scholars as well as interested laypeople were drawn to the event venues.
  • The livestream of the series on the Tang Prize Foundation's official YouTube channels also allowed a wider global audience to participate online in real time.

2022 Tang Prize Masters' Forum Series Sheds Light on Current Global Challenges

Retrieved on: 
Friday, October 14, 2022
History, Tang Prize, Sustainable development, RNA transfection, Therapy, Government, YouTube, Constitution, SM-102, Technology, Student, Gold, Sinology, Exercise, DRS, Language, Optimism, Speech, RNA, LNP, California Cultures in Comparative Perspective, COVID-19, Weather, Medical device

TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September.

Key Points: 
  • TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September.
  • Six 2022 laureates, Professor Jeffrey Sachs for Sustainable Development, Drs.
  • Tens of thousands of students, scholars as well as interested laypeople were drawn to the event venues.
  • The livestream of the series on the Tang Prize Foundation's official YouTube channels also allowed a wider global audience to participate online in real time.

Capstan Therapeutics Announces Appointment of Athena Countouriotis, M.D., as Board Chair and Strengthens Leadership Team with Key Appointment

Retrieved on: 
Wednesday, October 12, 2022
Stem Cells, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, LinkedIn, CA, Sunitinib, Therapy, RNA transfection, Bayer, Sale, Cell engineering, Autoimmune disease, Ambit, Athena, Chairperson, Pfizer, Investment, Patient, Biotechnology, Coronavirus Scientific Advisory Board (Turkey), Gene editing, SM-102, Tolerx, Leal, Technology, University, Daiichi Sankyo, Company, Acquisition, Ambit Biosciences, Turning Point, Board, CEO, Adverum Biotechnologies, Eli Lilly, Immunotherapy, RA, Fibrosis, Regenerative medicine, Bristol Myers Squibb, Polaris Partners, DVM, Degenerative disease, Engineering, Management, Pharmaceutical industry, Capstan

We are thrilled Athena will be leading our Board and providing senior counsel to our team from her deep experience leading the development of multiple development programs to approval.

Key Points: 
  • We are thrilled Athena will be leading our Board and providing senior counsel to our team from her deep experience leading the development of multiple development programs to approval.
  • She also serves on the Board of Directors of Iovance Biotherapeutics, Passage Bio, Recludix Pharma and Leal Therapeutics.
  • He is a member of the Board of Directors of Bright Peak and the Scientific Advisory Board of Avilar.
  • Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Retrieved on: 
Wednesday, September 14, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Other Health, RNA transfection, Research, Patient, Kite Pharma, Penn Institute for Urban Research, Perelman School of Medicine at the University of Pennsylvania, Technology, Cell, Drug development, Cell engineering, CAR, University, Fibrosis, FAP, Gorilla, Company, Investment, Kite, MBA, Translational medicine, Polaris Partners, LNP, SM-102, Laboratory, Lasker-DeBakey Clinical Medical Research Award, Pharming, CEO, Therapy, Engineering, LinkedIn, Immunotherapy, CA, RNA, Bristol Myers Squibb, Penn, Regenerative medicine, Pharmaceutical industry, Vaccine, Management, Capstan, Aghajanyan, DRS, Science

Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.

Key Points: 
  • Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.
  • Capstan is also pleased to announce that Laura Shawver, Ph.D., has joined the company as President and Chief Executive Officer.
  • Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells, said Dr. Shawver.
  • Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Retrieved on: 
Thursday, July 7, 2022
CMC, SM-102, View, Patient, CEO, Wuxi, Peptide, Industry, Contract manufacturing organization, Control, Therapy, LNP, Technology, SPPS, Contract research organization, Solution, Leadership, Oligonucleotide, Multimedia, Fine chemical, Manufacturing, Chemical substance

SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. 

Key Points: 
  • SHANGHAI, July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.
  • The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide,making more innovative therapies accessible to the patients.
  • oligonucleotide plant, WuXi STA extends its leadership in oligonucleotide development and manufacturing worldwide, with four large-scale oligonucleotide production lines and more than 20 small- to mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.
  • In addition, WuXi STA offers injectable formulation development and manufacturing services, including Lipid NanoParticle technology (LNP), as well as comprehensive analytical and Chemical, Manufacturing, and Controls (CMC) dossier preparation services, which further accelerate the development of new oligonucleotide and peptide therapeutics for the market.

Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA Gene Therapeutics With Nano-Drug Delivery Platform DegradaBALL®

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, Nanotechnology, Pharmaceutical, Surgery, Health, Technology, Genetics, Clinical Trials, Patent, Inc., CEO, CTO, Fibrosis, Biotechnology, Clinical trial, Investigational New Drug, Sirna, LNP, IND, COVID-19, 2009 Davis Cup, Incidence, RNA, Nanoparticle, Therapy, World Economic Forum, SM-102, Patient, SME, RNA interference, Ministry, Technology, Skin, Ministry (collective executive), Safety, Order of Science and Technology Merit, Quality of life, RNA transfection, Ministry of Food and Drug Safety, Liposome, Cytokine, MFDS, Ministry of SMEs and Startups, Pharmaceutical industry, Vaccine, Food, Science

LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars.

Key Points: 
  • LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars.
  • Instead of using excessive amounts of siRNA without any drug delivery system, Lemonex used their proprietary nano-drug delivery technology, DegradaBALL, to increase safety and high therapeutic outcomes with siRNA technology.
  • This phase 1 clinical trial is the first RNA gene therapy using Lemonexs DegradaBALL drug delivery platform technology, and designed to evaluate the safety on healthy participants.
  • Through the development of LEM-S401, I expect Lemonex to show more incredible outcomes with our DegradaBALL drug delivery technology in the global market by confirming the clinical safety data of DegradaBALL.